Sunandana Chandra, MD, Northwestern Medicine
Articles
Treatment Optimization for Patients With Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Future Treatment Landscape for Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Promising Late-Stage Trials in Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Targeted Therapy Versus IO for Relapsed/Refractory Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Novel Approaches for Relapsed/Refractory Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Management of Brain Metastases in Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
I/O Dosing Schedules in Metastatic Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Novel Therapies for Metastatic Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Systemic Therapy for Metastatic Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Adjuvant Therapy for Melanoma: Safety and Efficacy
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Adjuvant Therapy for Melanoma: Ongoing Studies of Interest
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Adjuvant Data Explored for Locally Advanced Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Neoadjuvant Data Explored for Locally Advanced Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
pCR and Neoadjuvant Therapy for Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Molecular Testing in Locally Advanced Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Identifying Patients for Neoadjuvant Melanoma Therapy
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Optimal Management of Locally Advanced Melanoma
Jeffrey S. Weber, MD, PhD, NYU Langone Health;Sunandana Chandra, MD, Northwestern Medicine;Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center;Ryan J. Sullivan, MD, Massachusetts General Hospital Cancer Center
June 23rd 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
